Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Profit After Tax: 2009-2025

Historic Profit After Tax for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to -$26.8 million.

  • Northwest Biotherapeutics' Profit After Tax fell 38.48% to -$26.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.8 million, marking a year-over-year decrease of 29.11%. This contributed to the annual value of -$83.8 million for FY2024, which is 33.83% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Profit After Tax stood at -$26.8 million, which was down 74.46% from -$15.4 million recorded in Q2 2025.
  • Northwest Biotherapeutics' Profit After Tax's 5-year high stood at $133.3 million during Q4 2021, with a 5-year trough of -$32.9 million in Q3 2022.
  • Over the past 3 years, Northwest Biotherapeutics' median Profit After Tax value was -$18.3 million (recorded in 2024), while the average stood at -$18.9 million.
  • Per our database at Business Quant, Northwest Biotherapeutics' Profit After Tax skyrocketed by 147.56% in 2021 and then slumped by 772.74% in 2022.
  • Over the past 5 years, Northwest Biotherapeutics' Profit After Tax (Quarterly) stood at $133.3 million in 2021, then slumped by 121.23% to -$28.3 million in 2022, then spiked by 50.61% to -$14.0 million in 2023, then slumped by 101.92% to -$28.2 million in 2024, then plummeted by 38.48% to -$26.8 million in 2025.
  • Its last three reported values are -$26.8 million in Q3 2025, -$15.4 million for Q2 2025, and -$19.3 million during Q1 2025.